Clinical trial
Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin as 2nd Line…
NCT00336583 · Asan Medical Center, Other · Completed
Key facts
| NCT number | NCT00336583 |
|---|---|
| Title | Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin as 2nd Line Therapy for Non-Hodgkin's Lymphoma (NHL) |
| Official title | Phase II Study of Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOX) for Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma |
| Lead sponsor | Asan Medical Center, Other |
| Collaborators | Boryung Pharmaceutical Co., Ltd Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Hodgkin's Lymphoma |
| Intervention type | Drug |
| Interventions | Oxaliplatin |
| Enrollment | 27 |
| Start date | Jun 1, 2006 |
| Primary completion | Dec 1, 2006 |
| Completion | Jan 1, 2008 |
| First posted | Jun 14, 2006 |
| Last update posted | Jun 26, 2018 |
| Countries | South Korea |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: